ImmunityBio reports $113 million revenue, 700% annual increase

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to ImmunityBio reports $113 million revenue, 700% annual increase

ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year

January 15, 2026 8:30 AM EST

ANKTIVA® sales momentum continues to trend upward with full year preliminary net product revenue of approximately $113.0 million, a ~700% increase year over year The three-month period ending December 31, 2025, preliminary net product revenue of approximately $38.3 million, surpassing net product revenue of $31.8 million in the prior quarter, a 20% quarter over quarter increase and a 431% increase over the three-month period ended December 31, 2024 ANKTIVA Unit Growth: 750% unit sales volume growth in 2025 compared to 2024 Approval Updates: The Saudi FDA (SFDA) granted approval of ANKTIVA® in combination with immune checkpoint inhibitors for adults with metastatic non-small cell lung cancer... More